deltatrials

Fred Hutchinson Cancer Center Clinical Trials

Sponsors / Fred Hutchinson Cancer Center

The ClinicalTrials.gov registry records 490 trials led by Fred Hutchinson Cancer Center. 47 trials are actively recruiting participants, 19 remain active without open enrollment, and 337 have concluded. 61 of these trials ended early via termination or withdrawal. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. The cumulative planned enrollment figure across all listed trials is 233,704 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.

490
Total Trials
47
Recruiting
19
Other Active
337
Completed
61
Terminated / Withdrawn
233,704
Total Enrollment

Termination reasons: Recruitment36% · Funding30% · Other18% · Efficacy8% · Safety5% · Regulatory3%

Recent Terminations

  • NCT04706507 Phase PHASE3 Stopped Apr 2025
    Acute Respiratory Failure
    "due to increased mortality and futility analyses"
  • NCT04809766 Phase PHASE1 Stopped Jan 2025
    Metastatic Pancreatic Ductal Adenocarcinoma
    "Study terminated due to end of funding."
  • NCT05831540 Phase NA Stopped Nov 2024
    Human Papillomavirus-Related Carcinoma
    "This study has been terminated due to the conclusion of funding. We were able to collect data on primary outcomes through pharmacy staff, but due to recruitment challenges were not able to complete secondary outcome recruitment."
  • NCT05304390 Phase NA Stopped Oct 2024
    Lung Carcinoma
    "Terminated due to end of funding. Enrollment sufficient to evaluate primary and secondary outcomes measures."
  • NCT04526288 Phase PHASE2 Stopped Aug 2023
    Acute Myeloid Leukemia
    "Terminated due to low accrual"
  • NCT04111497 Phase PHASE1/PHASE2 Stopped Aug 2023
    Chronic Graft Versus Host Disease
    "Study closed to accrual early due to side effects of study drug."
  • NCT05135650 Phase PHASE1 Stopped Jan 2023
    COVID-19 Infection
    "Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab"
  • NCT04083170 Phase PHASE2 Stopped Nov 2022
    Acute Erythroid Leukemia
    "The federal funding period ended. The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population \& smaller # of enrolling sites, we were not able to reach accrual goa"
  • NCT05291988 Phase NA Stopped Nov 2022
    Colorectal Carcinoma
    "Terminated due to low accrual"
  • NCT04639245 Phase PHASE1/PHASE2 Stopped Aug 2022
    Anatomic Stage IV Breast Cancer AJCC v8
    "Terminated due to slow accrual."

Active Trials (19 total)

Top Conditions

Top Locations